TMTetsuya Murata

Tetsuya Murata

*This is an algorithmically generated author record based on publicly available information.

Tetsuya Murata has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 5 February 2009
      • Vol. 28, 3711-6

    Lack of involvement of the GNAS1 T393C polymorphism in prostate cancer risk in a Japanese population.

    by Masatoshi Watanabe, Yoshifumi Hirokawa, Mayumi Tsuji, Makoto Yanagawa, Tetsuya Murata, Hiroyoshi Suzuki, Tomohiko Ichikawa, Takahiko Katoh, Yoshiki Sugimura, Taizo Shiraishi

    GNAS1 encodes the a-subunit of the Gs protein (Gsa), which binds GTP and stimulates adenylyl cyclase. Activating mutations lead to somatotroph, thyroid, adrenal and gonadal adenomas or the McCune-Albright syndrome and recently the T399C polymorphism in GNAS1 has been reported to be associated with malignancies. The purpose of the present case-control study with 349 Japanese prostate cancer patients and 203 urological controls was to determine whether the GNAS1 T393C polymorphism is associated with prostate cancer risk. The GNAS1 T393C polymorphism was examined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Odds ratios (OR) were adjusted for age using multiple logistic regression analysis with SPSS Medical Pack. The allele frequencies were compatible with the control population in Hardy-Weinberg equilibrium with 80, 169 and 100 for GNAS1 C/C, C/T and T/T, respectively in the patients with prostate cancer, compared with 42, 94 and 67 in the controls. No association between the GNAS1 polymorphism and prostate cancer risk was apparent. The C/C genotype was more frequent among the prostate cancer patients (22.9%) than the controls (20.7%), although without significance (OR, 1.30; 95% CI, 0.80-2.12; p=0.29). This pilot study does not support involvement of the GNAS1 polymorphism in prostate cancer risk.


    • 1 September 2004
      • Vol. 31  (9) , 1365-70

    [Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].

    by Hiroki Taoka, Hitomi Hirano, Yasushi Mitsui, Wataru Umino, Yu Nobuoka, Masako Yamashita, Kenji Tanigawa, Shyuji Yoshimine, Takazumi Imai, Shigenori Kadowaki, et al.

    The use of neoadjuvant chemotherapy for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors, especially for patients with Stage IV b (Japan criteria). We report our experience with a six-drug chemotherapeutic regimen that resulted in sufficient downstaging of the tumor in some patients to justify surgical resection. From Jan. 2001 through December 2003, 6 patients received 5-FU as a continuous infusion (200 mg/m2/day), calcium leucovorin weekly by intravenous bolus injection (30 mg/m2), mitomycin-C every 6 weeks (10 mg/m2 intravenously), and dipyridamole daily orally (75 mg), according to the UCLA regimen and gemcitabine weekly (600 mg/m2) and heparin as a continuous infusion (0-3,000 U/day) for locally advanced unresected pancreatic cancer. All of these patients were evaluable for response and survival. There were 5 partial responses (83% response rate) and 1 no response. Four of 5 responding patients had sufficient tumor regression to meet clinical criteria for resectability, three of whom underwent a curative resection. All patients who underwent downstage operation were still alive for the follow-up period (4-23 months).

    • 28 August 2004
      • Vol. 24  (4) , 2431-7

    Genetic polymorphisms of hormone-related genes and prostate cancer risk in the Japanese population.

    by Takahide Fukatsu, Yoshifumi Hirokawa, Tomio Araki, Takuichi Hioki, Tetsuya Murata, Hiroyoshi Suzuki, Tomohiko Ichikawa, Hiromasa Tsukino, Delai Qiu, Takahiko Katoh, et al.

    Carcinogenesis of the prostate involves androgen influences, and associations between genetic polymorphisms of androgen receptor and metabolizing enzymes and prostate cancer risk have been reported. Roles for non-androgenic hormones are not well defined, but they also may have an impact judging from epidemiological and animal experimental alphalambda zeta of data. The purpose of the study was to determine whether hormone-related polymorphisms are associated with prostate cancer risk. A case-control study was performed with 147 Japanese prostate cancer patients and 266 urological controls. Polymorphisms of target genes [cytochrome P450 (CYP) 1B1, Leu432Val; debrisoquine hydroxylase, (CYP2D6)*4; aromatase (CYP19), Arg264Cys; estrogen receptor (ER)alpha-Xx (Xba I) and Pp (Pvu II); ERbeta-Rr (Rsa I); progesterone receptor (PR) Alu in intron 7] were examined by PCR-based methods. The capital and small letters signify the absence and presence of restriction sites, respectively. Odds ratios (OR) were adjusted for age using multiple logistic regression analysis with SPSS Medical Pack. Among the seven examined genetic polymorphisms, significant associations between CYP1B1 Leu432Val (OR 4.80; 95% confidence interval (CI), 1.21-19.05) and Alu in intron 7 of PR (OR 4.17; 95%CI, 1.26-13.85) were found. As for combined effects, the CYP1B1 polymorphisms (Leu/Val+Val/Val) together with heterozygosity for Alu in the PR were more frequent among prostate cancer patients (1.45%) than controls (0.41%), although without significance (OR, 3.99; 95%CI, 0.36-44.8). The combination of ERalpha (P/p+p/p) polymorphisms with heterozygosity for Alu in the PR demonstrated an OR of 4.56 (95%CI, 1.01-20.6). This pilot study showed that CYP1B1 and PR polymorphisms, alone or in combination, might be associated with prostate cancer risk. They might, therefore, have potential as a tool for identifying high-risk individuals.


  • Esophageal anthracosis: Lesion mimicking malignant melanoma

    by Tetsuya Murata, Takazumi Imai, Ken-Ichiro Hoshino, Masami Kato, Kenji Tanigawa, Tetsuya Higuchi, Yuji Kozuka, Rie Inoue, Masatoshi Watanabe, Taizo Shiraishi, et al.


  • Successfully resected carcinosarcoma of the middle portion of the bile duct. Report of a case.

    by Toshio Iida, Kenji Tanigawa, Shun-Ichi Nakagawa, Takashi Higashiguchi, Toshizumi Imai, Tetsuya Murata


  • Gastrointestinal Stromal Tumors of the Small Intestine That Expressed c-kit Protein.

    by Natsuki Hoshino, Tetsuya Murata, Koji Oka, Keiki Kawakami, Ken-Ichiro Hoshino, Shigeyuki Sekoguchi, Taka-Aki Suga, Akira Nishimura, Masami Kato, Masayuki Hamada

    We report two patients with gastrointestinal stromal tumors (GISTs) of the small intestine that expressed c-kit protein (CD117). One was a 68-year-old woman with epigastralgia and vomiting. A submucosal tumor of the upper jejunum was detected, and partial resection was carried out. The histology revealed a GIST negative for CD34 but positive for CD117. The other was a 42-year-old woman with progressive anemia, melena and lower abdominal pain. Intussusception was detected, and a partial resection was carried out. A submucosal tumor of the lower jejunum was noted. The histology revealed a GIST positive for both CD34 and CD117.


  • A case of salivary duct carcinoma of the parotic gland.

    by Taizo Shiraishi, Tsuyoshi Nakayama, Masato Kitamoto, Hiroshi Nakano, Tetsuya Murata

    Cytologic findings of salivary duct carcinoma (SDC) of the parotic gland obtained by fine needle aspiration are described. The aspirates contained predominantly broad flat sheets and surrounding isolated cells. These were large polygonal epithelial cells with abundant eosinophilic cytoplasm, round to oval nuclei, fine granular chromatin and predominant nucleoli. Though some cells revealed intracytoplasmic lumen on histologic sections, this was inconspicuous cytologically.The cytologic differential diagnosis included mucoepidermoid carcinoma, oncocytic carcinoma, acinic cell carcinoma, and metastatic carcinoma. The presence of ICL has only been described in one article that demonstrated it electronmicroscopically.